Literature DB >> 18486483

TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration.

Ulkan Kilic1, Ertugrul Kilic, Christian M Matter, Claudio L Bassetti, Dirk M Hermann.   

Abstract

The pattern recognition receptor toll-like receptor (TLR)-4 mediates innate danger signaling in the brain, being activated in response to lipopolysaccharide. Until now, its role in the degenerating brain remained unknown. We here examined effects of a loss-of-function mutation of TLR-4 in mice submitted to transient focal cerebral ischemia and retinal ganglion cell (RGC) axotomy, which are highly reproducible and clinically relevant in vivo models of acute and subacute neuronal degeneration. We show that TLR-4 deficiency protects mice against ischemia and axotomy-induced RGC degeneration. Decreased phosphorylation levels of the mitogen-activated kinases ERK-1/-2, JNK-1/-2 and p38 together with reduced inducible NO synthase levels in injured neurons of TLR-4 mutant mice suggests that TLR-4 deficiency downscales parenchymal stress responses, thereby enhancing neuronal survival. At the same time, densities of MPO+ neutrophils and Iba1+ microglial cells were increased in the brains of TLR-4 mutant animals, pointing towards a futile inflammatory response aiming to compensate lost functions. Our data indicate that innate immunity may represent an attractive target for neuroprotective treatments in stroke and neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486483     DOI: 10.1016/j.nbd.2008.03.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  75 in total

1.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Regulation of microglial activation in stroke.

Authors:  Shou-Cai Zhao; Ling-Song Ma; Zhao-Hu Chu; Heng Xu; Wen-Qian Wu; Fudong Liu
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 3.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 4.  Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?

Authors:  Catherine E Downes; Peter J Crack
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Reduced photoreceptor death and improved retinal function during retinal degeneration in mice lacking innate immunity adaptor protein MyD88.

Authors:  Sarah Syeda; Amit K Patel; Tinthu Lee; Abigail S Hackam
Journal:  Exp Neurol       Date:  2015-02-25       Impact factor: 5.330

6.  Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Authors:  Dirk M Hermann
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 7.  Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use.

Authors:  Ulrich Dirnagl; Kyra Becker; Andreas Meisel
Journal:  Lancet Neurol       Date:  2009-04       Impact factor: 44.182

8.  Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons.

Authors:  Monica M Sauter; Aaron W Kolb; Curtis R Brandt
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

Review 9.  Linking oxidative stress to inflammation: Toll-like receptors.

Authors:  Roop Gill; Allan Tsung; Timothy Billiar
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

Review 10.  A clear and present danger: endogenous ligands of Toll-like receptors.

Authors:  Jacob A Sloane; Daina Blitz; Zachary Margolin; Timothy Vartanian
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.